Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lir Life SciencesBBCMF +300.00%12 Cash-to-Debt is No Debt (1) as of Jan. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates BBCMF with a GF Score™ of 12/100. Among 1,399 Biotechnology companies, Lir Life Sciences ranks better than 65.19% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Lir Life Sciences's cash to debt ratio for the quarter that ended in Jan. 2026 was No Debt (1).
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Lir Life Sciencescould pay off its debt using the cash in hand for the quarter that ended in Jan. 2026.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Lir Life Sciences's Cash-to-Debt or its related term are showing as below:
BBCMF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09 Med: No Debt Max: No Debt
Current: 26.31
During the past 2 years, Lir Life Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.09. And the median was No Debt.
BBCMF's Cash-to-Debt is ranked better than 65.19% of 1399
companies
in the Biotechnology industry
Industry Median: 6.49
vs BBCMF: 26.31
Lir Life Sciences (OTCPK:BBCMF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Lir Life Sciences Cash-to-Debt Related Terms
Lir Life Sciences Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Lir Life Sciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BBCMF vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, Lir Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lir Life Sciences Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lir Life Sciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Lir Life Sciences's Cash-to-Debt falls into.
Lir Life Sciences's Cash to Debt Ratio for the fiscal year that ended in Apr. 2025 is calculated as:
Lir Life Sciences had no debt (1).
Lir Life Sciences's Cash to Debt Ratio for the quarter that ended in Jan. 2026 is calculated as:
Lir Life Sciences had no debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash-to-Debt of No Debt <sup>(1)</sup> mean?
Lir Life Sciences (BBCMF) has a Cash-to-Debt of No Debt (1) as of Jan. 2026. This is 100% below median its historical median of 10,000.00. Over the past decade, Lir Life Sciences' Cash-to-Debt has ranged from 0.09 to 10,000.00. According to the industry distribution chart, Lir Life Sciences ranks #487 out of 1399 companies in the Biotechnology industry, placing it in the top 34.8%.
Is Lir Life Sciences' Cash-to-Debt too high?
Lir Life Sciences' current Cash-to-Debt of No Debt (1) is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 10,000.00. Based on the distribution chart, Lir Life Sciences ranks #487 out of 1399 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lir Life Sciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lir Life Sciences ranks #487 out of 1399 companies for Cash-to-Debt. This puts Lir Life Sciences in the upper half of its industry. The industry median Cash-to-Debt is 6.49. Historically, Lir Life Sciences' own Cash-to-Debt has ranged from 0.09 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.49, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lir Life Sciences's current Cash-to-Debt is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current Cash-to-Debt of No Debt (1). The current Cash-to-Debt is No Debt (1), which is 100% below median its 10-year median of 10,000.00. Lir Life Sciences' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current Cash-to-Debt is No Debt (1) as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
12GF Score
Get the complete analysis for BBCMF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBCMF has been successfully added to your 
